MiLaboratories and Miltenyi Biotec Announce Strategic Partnership to Advance Next Generation Therapies
April 29 2024 - 5:01AM
Business Wire
MiLaboratories, a leader in RNA immune technologies, and
Miltenyi Biotec, a global pioneer in biotechnology, are excited to
announce a landmark partnership that promises to revolutionize the
field of next-generation therapies. This collaboration combines
MiLaboratories' cutting-edge RNA kit technology for immune
sequencing with Miltenyi Biotec's robust production and
commercialization capabilities.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240429635132/en/
MiLaboratories & Miltenyi Biotec
partnership (Graphic: Business Wire)
Under this agreement, MiLaboratories will grant exclusive rights
to its innovative RNA kits immune sequencing technology to Miltenyi
Biotec. This technology has been instrumental in advancing research
and development in the field of immunology and personalized
medicine. Miltenyi Biotec will leverage its global reach and
expertise in biotechnology to produce and commercialize these kits,
making them widely available to researchers and clinicians
worldwide.
A cornerstone of this partnership is the integration of
MiLaboratories' renowned software solutions, MiXCR and Platforma,
into Miltenyi Biotec's offerings. These software platforms are
leaders in next-generation sequencing (NGS) data analysis,
providing powerful, user-friendly tools for genomic data
interpretation. Customers purchasing RNA kits from Miltenyi Biotec
will now benefit from seamless access to MiXCR and Platforma,
enhancing their research capabilities and efficiency.
"This partnership is a significant milestone in our mission to
accelerate the development of next-generation therapies," said Stan
Poslavsky, CEO of MiLaboratories. "By combining our innovative RNA
technologies and software platforms with Miltenyi Biotec's
manufacturing and commercial strengths, we are poised to make a
substantial impact in the field of genomics and personalized
medicine."
Jürgen Schmitz, Managing Director at Miltenyi Biotec, added, "We
are thrilled to partner with MiLaboratories, a company that shares
our commitment to advancing human health. Their RNA kits technology
for immune sequencing complements our molecular analysis product
portfolio perfectly. Moreover, their software solutions will offer
our customers unparalleled support in data analysis. Together, we
are building the future for next-generation therapies."
This partnership is expected to accelerate the pace of discovery
and development in the field of genomics, offering researchers and
clinicians new tools to explore the complexities of genetic
information and foster the development of innovative therapies.
About MiLaboratories
MiLaboratories is a leading developer of RNA kit technologies
and software solutions for NGS data analysis. With a focus on
innovation and precision, MiLaboratories' products are at the
forefront of genomics research and personalized medicine.
About Miltenyi Biotec
Miltenyi Biotec is a global leader empowering biomedical
research and advancing cellular therapy. The company's solutions
support all stages of cell and gene therapy product development
from process and analytical development to commercial-scale
manufacturing. With a commitment to excellence and innovation,
Miltenyi Biotec is dedicated to helping researchers and clinicians
around the world make a greater impact on science and health.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240429635132/en/
MiLaboratories Contact: Stan Poslavsky, CEO E-mail:
press@milaboratories.com https://milaboratories.com/
https://platforma.bio/
Miltenyi Biotec Contact: Kim Münster, Corporate Communications
E-mail: corpcom@miltenyi.com